Peptide Monograph

TB-500

Thymosin Beta-4 (Synthetic Fragment)

At a Glance

Mechanism of Action

TB-500 is a synthetic version of the naturally occurring 43-amino-acid peptide thymosin beta-4 (Tβ4), one of the most abundant intracellular peptides in mammalian cells. Thymosin beta-4 was originally isolated from bovine thymus tissue by Goldstein and colleagues in the 1960s as part of thymic hormone research, but its primary biological role is in the regulation of actin dynamics and tissue repair rather than immune modulation.[1]

The principal molecular function of Tβ4 is the sequestration of globular actin (G-actin). By binding monomeric G-actin in a 1:1 complex, Tβ4 maintains a reservoir of unpolymerized actin that can be rapidly mobilized for filamentous actin (F-actin) assembly when cells need to migrate, divide, or change shape. This G-actin buffering function is essential for cytoskeletal reorganization during wound healing and tissue repair.[2]

Tβ4 promotes cell migration through its central actin-binding domain, particularly the 17-amino-acid sequence known as Ac-SDKP (the N-terminal tetrapeptide released by enzymatic cleavage). The Ac-SDKP fragment has demonstrated independent anti-fibrotic and anti-inflammatory properties, inhibiting collagen deposition and inflammatory cell recruitment.[3]

Beyond actin regulation, Tβ4 promotes angiogenesis (new blood vessel formation) through upregulation of VEGF and activation of endothelial cell migration. Malinda et al. demonstrated that Tβ4 promotes angiogenesis in vitro and in the chick chorioallantoic membrane assay, and accelerates dermal wound healing in aged mice with improved wound contraction, collagen deposition, and angiogenesis.[4]

Tβ4 also downregulates pro-inflammatory cytokines including NF-kB, and has been shown to reduce inflammatory mediators in multiple injury models. In cardiac tissue, Tβ4 activates Akt (protein kinase B) signaling, promoting cardiomyocyte survival following ischemic injury, and has been shown to activate resident cardiac progenitor cells in murine myocardial infarction models.[5]

Evidence Summary

Animal Studies

The bulk of the evidence for thymosin beta-4 comes from preclinical animal research. Smart et al. demonstrated that Tβ4 activates epicardial progenitor cells and promotes neovascularization following myocardial infarction in mice, with improved cardiac function and reduced scar size.[5] These cardiac repair findings represent some of the most compelling preclinical data for Tβ4.

Malinda et al. showed that Tβ4 accelerates wound healing in a full-thickness dermal wound model in aged mice, with enhanced angiogenesis, collagen deposition, and wound contraction. The peptide promoted keratinocyte migration and increased matrix metalloproteinase expression, both essential for wound repair.[4]

Additional animal studies have demonstrated benefits in models of corneal injury (accelerated epithelial healing), traumatic brain injury (reduced inflammation, improved neurological outcomes), liver fibrosis (reduction in collagen I and alpha-smooth muscle actin expression), and musculoskeletal injury (enhanced muscle fiber repair).[3][6]

Human Clinical Evidence

RegeneRx Biopharmaceuticals has sponsored several human trials using the full thymosin beta-4 protein under the investigational drug designations RGN-259 (ophthalmic) and RGN-137 (dermal):

• Dry eye syndrome (RGN-259) — Phase II clinical trials of a topical Tβ4 ophthalmic solution for dry eye showed statistically significant improvements in ocular discomfort and corneal staining scores compared to vehicle, with a favorable safety profile. Sosne et al. published the results demonstrating both symptom relief and objective corneal healing markers.[6]
• Epidermolysis bullosa (RGN-137) — A small study of topical Tβ4 for junctional epidermolysis bullosa (a genetic blistering skin disease) showed accelerated wound healing in treated lesions compared to control sites.
• Pressure ulcers / chronic wounds — Early-stage trials of topical Tβ4 for chronic non-healing wounds showed trends toward accelerated closure, though large-scale confirmatory studies have not been completed.

It is critical to note that these human trials used pharmaceutical-grade full thymosin beta-4 protein in topical formulations, not injectable TB-500 fragment products from research chemical suppliers. The efficacy and safety of injectable commercial TB-500 in humans has not been established by any published clinical trial.

Primary Uses (in Research)

Based on the available preclinical and early clinical literature, TB-500/thymosin beta-4 has been investigated for the following applications:

• Tissue repair and wound healing — Enhanced dermal wound closure, collagen deposition, and keratinocyte migration in animal wound models. Phase II human data supports topical use for corneal and dermal wound healing.[4][6]
• Cardiac repair (post-myocardial infarction) — Activation of cardiac progenitor cells, promotion of neovascularization, and reduction of infarct scar size in murine MI models. This remains a preclinical finding with no human cardiac trial data available.[5]
• Hair regrowth — Tβ4 has been shown to stimulate hair follicle stem cells and promote hair growth in mouse models. The peptide's effects on hair follicle cycling and hair shaft formation have been documented, though human hair growth data is anecdotal.[3]
• Inflammation reduction — Downregulation of NF-kB and pro-inflammatory cytokines across multiple tissue injury models. The anti-fibrotic peptide fragment Ac-SDKP (derived from Tβ4) has independent anti-inflammatory properties.[3]
• Neuroprotection — Improved neurological outcomes and reduced inflammation in animal models of traumatic brain injury and stroke.
• Corneal healing — Accelerated corneal epithelial repair; the most advanced application in the clinical pipeline (Phase II for dry eye).[6]

Contraindications

Standard Protocols

Unlike BPC-157, which is typically injected locally near the injury site, TB-500 is generally administered systemically (e.g., abdomen, deltoid) because of its mechanism involving systemic upregulation of actin and cell-migration pathways. Local injection is not considered necessary due to the peptide's systemic distribution.

Common Stacks & Synergies

TB-500 is frequently combined with other peptides in self-experimentation protocols. The following combinations are commonly reported but lack published clinical evidence supporting their combined use:

• TB-500 + BPC-157 — The most widely discussed peptide healing stack. The proposed rationale is that TB-500's systemic actin-upregulation and cell-migration effects complement BPC-157's local angiogenic and growth-factor-mediated repair. TB-500 is typically injected systemically while BPC-157 is injected locally near the injury. No controlled studies have evaluated this combination.
• TB-500 + GH Secretagogues (CJC-1295/Ipamorelin) — Some protocols add growth hormone secretagogues to amplify the anabolic and regenerative environment. The rationale is that elevated GH and IGF-1 levels may enhance the tissue repair promoted by TB-500.
• TB-500 + PRP (Platelet-Rich Plasma) — Some integrative medicine practitioners have explored combining TB-500 with PRP injections, theorizing that the growth factors in PRP would complement TB-500's cell-migration-promoting effects.

Preparation & Administration

TB-500 is supplied as a lyophilized (freeze-dried) powder in vials, typically containing 2 mg or 5 mg of peptide. It must be reconstituted with bacteriostatic water before injection.

Reconstitution

For a standard 5 mg vial reconstituted with 1 mL of bacteriostatic water, each 0.1 mL (10 units on a standard insulin syringe) delivers 500 mcg (0.5 mg). For a 2.5 mg dose, draw 0.5 mL (50 units). For detailed step-by-step reconstitution instructions and a concentration calculator, see the Reconstitution Guide.

Injection

TB-500 is typically administered via subcutaneous injection in the abdominal area, thigh, or deltoid. Because TB-500 works systemically (rather than locally), injection site proximity to the injury is not considered critical. Use a 29–31 gauge insulin syringe. Rotate injection sites between administrations to prevent lipodystrophy. For injection technique, site selection, and sterile procedure, see the Injection Safety Guide.

Injection Volume Note

Because TB-500 doses are significantly larger than BPC-157 doses (milligrams vs. micrograms), the injection volume is correspondingly larger. A 5 mg dose from a 5 mg/mL reconstitution requires injecting 1 mL, which is the full capacity of a standard insulin syringe. Some users prefer to reconstitute with a smaller volume (e.g., 0.5 mL) and split into two injection sites to reduce discomfort.

Side Effects & Adverse Events

In the RegeneRx clinical trials using topical thymosin beta-4 (RGN-259, RGN-137), the peptide was well tolerated with no drug-related serious adverse events reported. The most common side effects were mild and transient local reactions at the application site.[6]

In animal studies, Tβ4 has shown a favorable safety profile at pharmacologically relevant doses. No significant organ toxicity has been observed in preclinical toxicology studies.[3]

Self-reported side effects from community use of injectable TB-500 (unverified):

• Fatigue and temporary lethargy (most commonly reported, typically in the first 1–2 weeks)
• Headache (moderate frequency)
• Injection site irritation, redness, or mild pain
• Nausea (infrequent)
• Head rush or lightheadedness shortly after injection (infrequent)
• Mild flu-like symptoms during initial loading phase (rare)

The fatigue and lethargy reported with TB-500 is a notable difference from BPC-157, which typically does not produce systemic side effects. The larger dosing (milligrams vs. micrograms) and systemic distribution of TB-500 may account for this difference.

Drug Interactions

No formal drug interaction studies have been conducted with TB-500 or injectable thymosin beta-4 in humans. The following theoretical interactions are based on the peptide's known pharmacological mechanisms:

• Anticoagulants (warfarin, heparin, DOACs) — TB-500's pro-angiogenic properties and effects on cell migration could theoretically influence hemostasis or interact with anticoagulant pharmacodynamics. Monitor closely if combining.
• Immunosuppressants (cyclosporine, tacrolimus, corticosteroids) — Thymosin beta-4 has immunomodulatory properties. Exogenous administration could theoretically alter immune function in ways that interact with immunosuppressive therapy. The direction and magnitude of such an interaction is unknown.
• Anti-cancer therapies — Given TB-500's promotion of angiogenesis and cell proliferation, theoretical antagonism with anti-angiogenic cancer therapies (bevacizumab, sunitinib) is possible. Concurrent use with any cancer therapy should be avoided.
• ACE inhibitors — The Tβ4 fragment Ac-SDKP is a natural substrate for angiotensin-converting enzyme (ACE). ACE inhibitors increase endogenous Ac-SDKP levels. Exogenous Tβ4 administration in patients on ACE inhibitors could theoretically result in elevated Ac-SDKP levels with unknown consequences.

Storage & Handling

Do not freeze reconstituted solution. Protect from prolonged light exposure. If the solution appears cloudy, discolored, or contains particulate matter, discard the vial. Use bacteriostatic water (not sterile water) for reconstitution to provide antimicrobial preservation for multi-dose use. Note that reconstituted TB-500 has a shorter recommended stability window (14–21 days) than BPC-157 (28 days).

Legal & Regulatory Status

• FDA (United States) — TB-500 is not approved for any indication. It is not scheduled as a controlled substance. Sold under the research chemical designation "not for human consumption." The full thymosin beta-4 protein has investigational new drug (IND) applications through RegeneRx Biopharmaceuticals for specific ophthalmic and dermal indications.
• WADA (World Anti-Doping Agency) — Thymosin beta-4 is explicitly listed on the WADA Prohibited List under section S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics). It is banned at all times (both in-competition and out-of-competition). Athletes subject to WADA testing must not use TB-500.
• European Union — Not approved as a medicinal product. Available as a research chemical with varying regulatory status by member state.
• Australia (TGA) — Not approved. Classified as a Schedule 4 prescription-only substance under the Poisons Standard. Its use in horse racing has led to notable regulatory enforcement in Australian racing jurisdictions.
• Horse racing — TB-500 has been widely used in equine veterinary practice and horse racing, leading to bans by multiple racing authorities worldwide. This has been a major driver of its public profile and regulatory scrutiny.

Open Questions

Significant gaps remain in the TB-500/thymosin beta-4 evidence base. Key unresolved questions include:

• Fragment vs. full protein efficacy — It is unclear whether commercial TB-500 products (which may contain fragments of varying lengths) have equivalent bioactivity to the full 43-amino-acid thymosin beta-4 protein used in published research. This is a fundamental confound in applying the literature to commercial products.
• Human dosing optimization — No dose-finding studies have been conducted for injectable TB-500 in humans. Current protocols are based on allometric extrapolation and community experience, not pharmacokinetic/pharmacodynamic studies.
• Cancer risk from chronic angiogenesis promotion — The long-term safety implications of repeated exogenous angiogenesis promotion are unknown. Whether TB-500 increases, decreases, or has no effect on cancer incidence is an open and important question.
• Synergy with BPC-157 — The TB-500 + BPC-157 stack is widely used but has never been evaluated in a controlled study. Whether the combination produces synergistic, additive, or antagonistic effects is unknown.
• Optimal administration route — While subcutaneous injection is standard, the comparative bioavailability and efficacy of intramuscular, intravenous, or other routes have not been characterized for injectable TB-500.
• Product quality and consistency — As an unregulated research chemical, the purity, accurate peptide content, sterility, and endotoxin levels of commercially available TB-500 products cannot be guaranteed.

Bibliography

1. Goldstein AL, Slater FD, White A. "Preparation, assay, and partial purification of a thymic lymphocytopoietic factor (thymosin)." Proc Natl Acad Sci U S A. 1966;56(3):1010-7. doi:10.1073/pnas.56.3.1010. PMID:5230128.
2. Safer D, Elzinga M, Nachmias VT. "Thymosin beta 4 and Fx, an actin-sequestering peptide, are indistinguishable." J Biol Chem. 1991;266(7):4029-32. PMID:1999398.
3. Goldstein AL, Hannappel E, Sosne G, Kleinman HK. "Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications." Expert Opin Biol Ther. 2012;12(1):37-51. doi:10.1517/14712598.2012.634793. PMID:22171665.
4. Malinda KM, Sidhu GS, Mani H, Banaudha K, Maheshwari RK, Goldstein AL, Kleinman HK. "Thymosin beta4 accelerates wound healing." J Invest Dermatol. 1999;113(3):364-8. doi:10.1046/j.1523-1747.1999.00708.x. PMID:10469334.
5. Smart N, Risebro CA, Melville AA, Moses K, Schwartz RJ, Chien KR, Riley PR. "Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization." Nature. 2007;445(7124):177-82. doi:10.1038/nature05383. PMID:17108969.
6. Sosne G, Qiu P, Ousler GW 3rd, Dunn SP, Crockford D. "Thymosin beta4 and the eye: I can see clearly now the pain is gone." Ann N Y Acad Sci. 2012;1270:89-95. doi:10.1111/j.1749-6632.2012.06739.x. PMID:23050823.